166 related articles for article (PubMed ID: 18495645)
1. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.
Keefe RS; Harvey PD
Schizophr Bull; 2008 Jul; 34(4):656-63. PubMed ID: 18495645
[TBL] [Abstract][Full Text] [Related]
2. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.
Barch DM; Carter CS;
Schizophr Bull; 2008 Jul; 34(4):613-8. PubMed ID: 18499705
[TBL] [Abstract][Full Text] [Related]
3. Building a clinically relevant cognitive task: case study of the AX paradigm.
MacDonald AW
Schizophr Bull; 2008 Jul; 34(4):619-28. PubMed ID: 18487225
[TBL] [Abstract][Full Text] [Related]
4. Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change.
Silverstein SM
Schizophr Bull; 2008 Jul; 34(4):645-55. PubMed ID: 18468987
[TBL] [Abstract][Full Text] [Related]
5. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
6. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
[TBL] [Abstract][Full Text] [Related]
7. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
Carter CS; Barch DM
Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
[TBL] [Abstract][Full Text] [Related]
8. The translation of cognitive paradigms for patient research.
Luck SJ; Gold JM
Schizophr Bull; 2008 Jul; 34(4):629-44. PubMed ID: 18487226
[TBL] [Abstract][Full Text] [Related]
9. The MATRICS consensus cognitive battery: what we know 6 years later.
Green MF; Harris JG; Nuechterlein KH
Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
[No Abstract] [Full Text] [Related]
10. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Keefe RS; Goldberg TE; Harvey PD; Gold JM; Poe MP; Coughenour L
Schizophr Res; 2004 Jun; 68(2-3):283-97. PubMed ID: 15099610
[TBL] [Abstract][Full Text] [Related]
11. Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties.
Kern RS; Penn DL; Lee J; Horan WP; Reise SP; Ochsner KN; Marder SR; Green MF
Schizophr Bull; 2013 Nov; 39(6):1201-10. PubMed ID: 24072805
[TBL] [Abstract][Full Text] [Related]
12. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
Buchanan RW
Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
[No Abstract] [Full Text] [Related]
13. Adapting social neuroscience measures for schizophrenia clinical trials, Part 1: ferrying paradigms across perilous waters.
Green MF; Lee J; Ochsner KN
Schizophr Bull; 2013 Nov; 39(6):1192-200. PubMed ID: 24072811
[TBL] [Abstract][Full Text] [Related]
14. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia.
Bromley E
Psychiatr Serv; 2007 Apr; 58(4):475-81. PubMed ID: 17412848
[TBL] [Abstract][Full Text] [Related]
15. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment of cognition in schizophrenia: an idea whose method has come.
Harvey PD; Cornblatt BA
Am J Psychiatry; 2008 Feb; 165(2):163-5. PubMed ID: 18245181
[No Abstract] [Full Text] [Related]
17. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
18. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.
Keefe RS; Vinogradov S; Medalia A; Silverstein SM; Bell MD; Dickinson D; Ventura J; Marder SR; Stroup TS
Schizophr Bull; 2011 Sep; 37(5):1057-65. PubMed ID: 20194249
[TBL] [Abstract][Full Text] [Related]
19. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Heinrichs RW
Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
[No Abstract] [Full Text] [Related]
20. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]